CU23872B1 - Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina - Google Patents

Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina

Info

Publication number
CU23872B1
CU23872B1 CU20080088A CU20080088A CU23872B1 CU 23872 B1 CU23872 B1 CU 23872B1 CU 20080088 A CU20080088 A CU 20080088A CU 20080088 A CU20080088 A CU 20080088A CU 23872 B1 CU23872 B1 CU 23872B1
Authority
CU
Cuba
Prior art keywords
antibodies against
against peptide
directed antibodies
peptide related
antagonist directed
Prior art date
Application number
CU20080088A
Other languages
English (en)
Other versions
CU20080088A7 (es
Inventor
Joerg Zeller
Kristian Todd Poulsen
Yasmina Noubia Abdiche
Jaume Pons
Sierra Jones Collier
Arnon Rosenthal
Original Assignee
Rinat Neuroscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37909474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU23872(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rinat Neuroscience Corp filed Critical Rinat Neuroscience Corp
Publication of CU20080088A7 publication Critical patent/CU20080088A7/es
Publication of CU23872B1 publication Critical patent/CU23872B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CU20080088A 2005-11-14 2008-05-14 Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina CU23872B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73662305P 2005-11-14 2005-11-14
PCT/IB2006/003181 WO2007054809A2 (en) 2005-11-14 2006-11-02 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Publications (2)

Publication Number Publication Date
CU20080088A7 CU20080088A7 (es) 2012-06-21
CU23872B1 true CU23872B1 (es) 2013-03-27

Family

ID=37909474

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20080088A CU23872B1 (es) 2005-11-14 2008-05-14 Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina

Country Status (38)

Country Link
US (20) US8007794B2 (es)
EP (6) EP3045182B1 (es)
JP (1) JP5123197B2 (es)
KR (2) KR20080068062A (es)
CN (2) CN101309704B (es)
AP (1) AP2008004467A0 (es)
AU (1) AU2006313434B2 (es)
BR (1) BRPI0618705B8 (es)
CA (1) CA2626120C (es)
CR (1) CR9975A (es)
CU (1) CU23872B1 (es)
CY (3) CY1120249T1 (es)
DK (3) DK3045182T3 (es)
EA (1) EA015526B1 (es)
EC (1) ECSP088451A (es)
ES (3) ES2433251T5 (es)
GE (1) GEP20115333B (es)
HK (2) HK1125837A1 (es)
HR (2) HRP20180752T1 (es)
HU (3) HUE036940T2 (es)
IL (3) IL190876A (es)
LT (3) LT3045182T (es)
LU (2) LUC00119I2 (es)
MA (1) MA30136B1 (es)
ME (1) ME00419B (es)
MY (1) MY153249A (es)
NL (1) NL300997I2 (es)
NO (3) NO344099B1 (es)
NZ (1) NZ568237A (es)
PL (3) PL1957106T5 (es)
PT (3) PT2380592T (es)
RS (3) RS57194B1 (es)
SI (3) SI3045182T1 (es)
SV (1) SV2008002905A (es)
TN (1) TNSN08213A1 (es)
UA (1) UA94244C2 (es)
WO (1) WO2007054809A2 (es)
ZA (1) ZA200803484B (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2380592T (pt) 2005-11-14 2018-06-06 Teva Pharmaceuticals Int Gmbh Anticorpos antagonistas dirigidos contra o péptido relacionado com o gene da calcitonina e métodos utilizando os mesmos
BRPI0908276B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
MX2010009722A (es) * 2008-03-04 2010-09-30 Pfizer Ltd Procedimiento de tratamiento del dolor cronico.
US20090258040A1 (en) * 2008-04-09 2009-10-15 Pherin Pharmaceuticals, Inc. Steroid treatment for hot flashes
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
EP2409067B1 (en) 2009-03-16 2019-12-11 Colder Products Company Aseptic coupling devices
BR112012004464B8 (pt) * 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
MX348562B (es) 2011-02-10 2017-06-20 Velos Media Int Ltd Dispositivo de procesamiento de imagenes y metodo de procesamiento de imagenes.
CN107827982B (zh) * 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
ES2873837T3 (es) * 2011-05-20 2021-11-04 H Lundbeck As Composiciones anti CGRP y uso de las mismas
CN108359008B (zh) * 2011-05-20 2022-03-29 H.伦德贝克公司 抗cgrp或抗cgrp-r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
EP3272769B1 (en) * 2012-01-26 2020-06-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
EP3024532B1 (en) 2013-07-23 2019-01-02 Colder Products Company Aseptic coupling devices
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RS65360B1 (sr) * 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
WO2015176017A1 (en) * 2014-05-16 2015-11-19 Salk Institute For Biological Studies Compositions and methods for treating metabolic disorders
EP3180069B1 (en) 2014-08-17 2020-05-13 Nine Continents Medical, Inc. Miniature implatable neurostimulator system for sciatic nerves and their branches
WO2016044224A1 (en) * 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
JO3669B1 (ar) * 2015-01-06 2020-08-27 Ferring Bv بيبتيدات مضَادَّة لببتيد المرتبط بجين الكالسيتونين
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
MX2018003713A (es) * 2015-09-24 2018-08-15 Teva Pharmaceuticals Int Gmbh Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente).
CA3007018A1 (en) * 2016-01-28 2017-08-03 Eli Lilly And Company Cgrp antibodies and uses thereof
WO2017136195A1 (en) 2016-02-01 2017-08-10 Eli Lilly And Company Parathyroid hormone – anti-rankl antibody fusion compounds
KR102444717B1 (ko) 2016-04-15 2022-09-16 하. 룬드벡 아크티에셀스카브 인간화 항-pacap 항체 및 그의 용도
WO2018022628A1 (en) * 2016-07-25 2018-02-01 Cephalon, Inc. Affinity chromatography wash buffer
EP3506925B1 (en) 2016-09-02 2023-09-06 Christopher J. Soares Use of cgrp receptor antagonists in treating glaucoma
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
MX2019003338A (es) * 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento de cefalea en racimos.
CN106442967B (zh) * 2016-09-27 2018-05-15 鸿运华宁（杭州）生物医药有限公司 一种检测跨膜蛋白单克隆抗体亲和力的方法
GB2557655A (en) 2016-12-14 2018-06-27 Teva Pharma Medical injection device packaging
WO2018160897A1 (en) 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center, Inc. Preventing post-ictal headaches
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2018237159A1 (en) 2017-06-21 2018-12-27 Cephalon, Inc. WASH PAD FOR CATIONIC EXCHANGE CHROMATOGRAPHY
TWI831762B (zh) 2018-01-12 2024-02-11 美商安進公司 Pac1抗體及其用途
JP2021518748A (ja) * 2018-02-23 2021-08-05 アールイーエムディー バイオセラピューティクス，インコーポレイテッドＲＥＭＤ Ｂｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体
US11295402B2 (en) 2018-03-28 2022-04-05 Bank Of America Corporation Blockchain-based property repair
US10498808B2 (en) 2018-03-28 2019-12-03 Bank Of America Corporation Blockchain-based property management
US11475422B2 (en) 2018-03-28 2022-10-18 Bank Of America Corporation Blockchain-based property management
BR112020019882A2 (pt) 2018-04-02 2021-01-05 Amgen Inc. Composições de erenumabe e seus usos
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
CN116328103A (zh) 2018-09-20 2023-06-27 梯瓦制药国际有限责任公司 自动注射器和用于老化的预填充针筒的注射弹簧
SG11202107046YA (en) * 2018-12-31 2021-07-29 United Neuroscience Ltd Peptide immunogens targeting calcitonin gene-related peptide (cgrp) and formulations thereof for prevention and treatment of migraine
SG11202106766SA (en) * 2019-01-08 2021-07-29 H Lundbeck As Acute treatment and rapid treatment of headache using anti-cgrp antibodies
WO2021040830A1 (en) 2019-08-27 2021-03-04 Colder Products Company Single-use genderless aseptic fluid couplings
US20210077591A1 (en) * 2019-09-09 2021-03-18 The University Of Chicago Combination therapy for the treatment of migraines
CN112274302B (zh) * 2020-11-24 2021-07-13 四川大学华西医院 一种多单元可调的智能化椎间融合器
IT202000029459A1 (it) * 2020-12-03 2022-06-03 Alberto Chiarugi Terapia dei disturbi emotivi
MX2023010115A (es) 2021-03-02 2023-11-09 Cgrp Diagnostics Gmbh Tratamiento y/o reducción de la aparición de la migraña.
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
WO2023139542A1 (en) * 2022-01-21 2023-07-27 Institut Pasteur De Montevideo Active immunization for reducing osteoarthritic, neuropathic, and cancer pain
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US4814567A (en) 1987-07-08 1989-03-21 Darko Jorge Lazaneo Dragicevic Electro-thermic resonance system for heating liquid
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0832980B1 (en) 1989-01-23 2002-06-19 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
JP3250802B2 (ja) 1989-03-21 2002-01-28 バイカル・インコーポレイテッド 脊椎動物における外因性ポリヌクレオチド配列の発現
US6673776B1 (en) 1989-03-21 2004-01-06 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
EP0408294B1 (en) 1989-07-10 1995-09-20 Amylin Pharmaceuticals, Inc. Use of an amylin antagonist for the manufacture of amedicament for the treatment of obesity and essential hypertension and related disorders
AU648261B2 (en) 1989-08-18 1994-04-21 Novartis Vaccines And Diagnostics, Inc. Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ZA911974B (en) 1990-03-21 1994-08-22 Res Dev Foundation Heterovesicular liposomes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
WO1993003769A1 (en) 1991-08-20 1993-03-04 THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTEMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
DE4139664A1 (de) 1991-12-02 1993-06-03 Diagen Inst Molekularbio Vorrichtung und verfahren zur isolierung und reinigung von nukleinsaeuren
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993025234A1 (en) 1992-06-08 1993-12-23 The Regents Of The University Of California Methods and compositions for targeting specific tissue
CA2137361A1 (en) 1992-06-10 1993-12-23 W. French Anderson Vector particles resistant to inactivation by human serum
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994012649A2 (en) 1992-12-03 1994-06-09 Genzyme Corporation Gene therapy for cystic fibrosis
DE4242396C2 (de) 1992-12-09 1995-01-05 Helopharm Petrik Co Kg Aralkyldiaminderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
AU6524794A (en) 1993-03-24 1994-10-11 Amylin Pharmaceuticals, Inc. Cloned receptors and methods for screening
AU6818094A (en) 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
WO1995000655A1 (en) 1993-06-24 1995-01-05 Mc Master University Adenovirus vectors for gene therapy
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ATE257176T1 (de) 1993-09-15 2004-01-15 Chiron Corp Rekombinanter alphavirus vektor
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
ATE196248T1 (de) 1993-11-16 2000-09-15 Skyepharma Inc Vesikel mit gesteuerter wirkstofffreisetzung
JPH07196700A (ja) 1994-01-06 1995-08-01 Sando Yakuhin Kk 抗カルシトニン抗体及びその作製方法、並びに該抗体を用いたカルシトニンの測定方法
US6436908B1 (en) 1995-05-30 2002-08-20 Duke University Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
ES2297831T3 (es) 1994-05-09 2008-05-01 Oxford Biomedica (Uk) Limited Vectores retroviricos que presentan una tasa de recombinacion reducida.
ATE265466T1 (de) 1994-08-16 2004-05-15 Human Genome Sciences Inc Calcitoninrezeptor
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
FR2732222B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
FR2732220B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les lichens et les prurits et composition obtenue
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
EP0737471A3 (fr) 1995-04-10 2000-12-06 L'oreal Utilisation d'un sel d'une métal alcalino-terreux comme inhibiteur de TNF-alpha dans une composition unique et composition obtenue
FR2732598B1 (fr) 1995-04-10 1997-05-09 Oreal Utilisation de sel de metaux alcalino-terreux pour le traitement des prurits et des dysesthesies oculaires ou palpebraux
EP1978033A3 (en) * 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
EP0851759A4 (en) * 1995-09-05 2000-12-06 Smithkline Beecham Corp COMPOUNDS AND RELATED METHODS
AU2731797A (en) 1996-04-15 1997-11-19 University Of Miami Molecular clone of cgrp receptor component protein and uses thereof
ATE424463T1 (de) 1996-05-06 2009-03-15 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
US5746694A (en) 1996-05-16 1998-05-05 Wilk; Peter J. Endoscope biopsy channel liner and associated method
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
JP3734315B2 (ja) 1996-08-26 2006-01-11 株式会社小松製作所 曲げ加工方法および曲げ加工装置
CA2264942A1 (en) * 1996-09-09 1998-03-12 Smithkline Beecham Corporation Compounds and methods
EA004037B1 (ru) 1996-09-10 2003-12-25 Др. Карл Томэ ГмбХ Модифицированные аминокислоты и лекарственное средство на их основе
WO1998056779A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation 4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US20030069231A1 (en) 1999-10-12 2003-04-10 Klaus Rudolf Modified aminoacids, pharmaceuticals containing these compounds and method for their production
US6376471B1 (en) 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9809839D0 (en) * 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
EP1117662A1 (en) 1998-09-30 2001-07-25 Merck Sharp & Dohme Limited Benzimidazolinyl piperidines as cgrp ligands
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en) * 1999-03-02 2001-11-06 Boehringer Ingelheim Pharma Kg Antagonists of calcitonin gene-related peptide
AU3734900A (en) 1999-03-09 2000-09-28 University Of Southern California Method of promoting myocyte proliferation and myocardial tissue repair
US6521609B1 (en) 1999-08-10 2003-02-18 Boehringer Ingelheim Pharma Kg Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20020162125A1 (en) 2001-03-06 2002-10-31 Anne-Marie Salmon Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
CA2461917C (en) 2001-09-27 2012-01-17 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US6767056B2 (en) 2002-01-14 2004-07-27 Shin Yeh Enterprise Co., Ltd. Settee with a foldable tray-support unit
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
CN1326879C (zh) 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
US7879991B2 (en) 2002-05-06 2011-02-01 Noxxon Pharma Ag CGRP binding nucleic acids
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en) 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
PL374017A1 (en) * 2002-06-05 2005-09-19 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
MXPA05001649A (es) * 2002-08-12 2005-05-27 Birkir Sveinsson Uso de compuestos antagonistas del cgrp para tratamiento de la psoriasis.
DE10250082A1 (de) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7285269B2 (en) 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
HUE026089T2 (hu) 2002-12-24 2016-05-30 Rinat Neuroscience Corp NGF elleni antitestek és eljárás alkalmazásukra
US7189722B2 (en) 2003-03-14 2007-03-13 Merck & Co., Inc. Aryl spirohydantoin CGRP receptor antagonists
EP1613368B1 (en) * 2003-03-14 2011-11-30 Merck Sharp & Dohme Corp. Carboxamide spirohydantoin cgrp receptor antagonists
AU2004226018B2 (en) * 2003-03-14 2009-08-27 Merck Sharp & Dohme Corp. Benzodiazepine spirohydantoin CGRP receptor antagonists
CA2519475A1 (en) * 2003-03-14 2004-09-30 Merck & Co., Inc. Bicyclic anilide spirohydantoin cgrp receptor antagonists
EP1606264B1 (en) * 2003-03-14 2012-05-02 Merck Sharp & Dohme Corp. Monocyclic anilide spirohydantoin cgrp receptor antagonists
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
EP1615914B1 (en) 2003-04-15 2010-05-05 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
US20060173046A1 (en) 2003-07-15 2006-08-03 Bell Ian M Hydroxypyridine cgrp receptor antagonists
DE102004008261B3 (de) 2004-02-20 2005-09-29 Mtu Friedrichshafen Gmbh Verfahren zur Steuerung und Regelung einer Brennkraftmaschinen-Generator-Einheit
WO2005084672A1 (de) 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en) * 2004-04-15 2007-10-09 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004018794A1 (de) * 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
CA2563687A1 (en) 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
TWI432196B (zh) 2005-01-18 2014-04-01 Euro Celtique Sa 內臟痛的治療
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
EP1928452A4 (en) 2005-08-25 2010-09-01 Wex Medical Ltd USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
EP2179741B1 (en) 2005-08-26 2014-10-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment of headaches by administraton of oxytocin
CA3008270A1 (en) 2005-09-21 2007-03-29 The Regents Of The University Of California Systems, compositions, and methods for local imaging and treatment of pain
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
PT2380592T (pt) 2005-11-14 2018-06-06 Teva Pharmaceuticals Int Gmbh Anticorpos antagonistas dirigidos contra o péptido relacionado com o gene da calcitonina e métodos utilizando os mesmos
AU2006316626A1 (en) 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
US7834000B2 (en) 2006-06-13 2010-11-16 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
WO2008011190A1 (en) 2006-07-21 2008-01-24 Vertex Pharmaceuticals Incorporated Cgrp receptor antagonists
MX2010009722A (es) 2008-03-04 2010-09-30 Pfizer Ltd Procedimiento de tratamiento del dolor cronico.
BRPI0908276B8 (pt) 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
WO2010006168A2 (en) 2008-07-09 2010-01-14 University Of Rochester Methods of treating cancer using and agent that modulates activity of the calcitonin-gene related peptide ("cgrp") receptor
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
BR112012004464B8 (pt) 2009-08-28 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para preparar uma composição farmacêutica para tratar e/ou prevenir dor visceral e/ou um ou mais sintomas de dor visceral, em que a dor visceral está associada á cistite intersticial (ic), e dita composição farmacêutica
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
CN107827982B (zh) 2011-05-20 2021-07-06 H.伦德贝克公司 抗cgrp抗体和抗体片段用于在有需要的受试者中预防或抑制畏光或厌光的用途
ES2873837T3 (es) 2011-05-20 2021-11-04 H Lundbeck As Composiciones anti CGRP y uso de las mismas
US10249132B2 (en) 2012-10-29 2019-04-02 Netent Product Services Ltd. Architecture for multi-player, multi-game, multi-table, multi-operator and multi-jurisdiction live casino gaming
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same

Also Published As

Publication number Publication date
US20170081395A1 (en) 2017-03-23
US20170240622A1 (en) 2017-08-24
EP2380592A3 (en) 2012-06-06
HK1225627B (zh) 2017-09-15
CN103421114B (zh) 2017-09-22
AP2008004467A0 (en) 2008-06-30
RS57192B1 (sr) 2018-07-31
EP1957106B1 (en) 2013-10-16
HRP20180753T1 (hr) 2018-08-24
KR20080068062A (ko) 2008-07-22
LT3045182T (lt) 2018-05-10
CN101309704A (zh) 2008-11-19
HRP20180752T1 (hr) 2018-06-15
US20190092841A1 (en) 2019-03-28
EP3842458A1 (en) 2021-06-30
TNSN08213A1 (fr) 2009-10-30
CN103421114A (zh) 2013-12-04
US9340614B2 (en) 2016-05-17
NZ568237A (en) 2011-11-25
US9890210B2 (en) 2018-02-13
US20150361172A1 (en) 2015-12-17
US9884907B2 (en) 2018-02-06
US9328168B2 (en) 2016-05-03
US20150050267A1 (en) 2015-02-19
DK1957106T4 (da) 2019-10-28
US9346881B2 (en) 2016-05-24
CY1120267T1 (el) 2019-07-10
US20150361173A1 (en) 2015-12-17
EP3045182A1 (en) 2016-07-20
HUE036940T2 (hu) 2018-08-28
NO20081854L (no) 2008-05-19
IL248025A0 (en) 2016-11-30
US8597649B2 (en) 2013-12-03
EA200801094A1 (ru) 2008-10-30
ES2664421T3 (es) 2018-04-19
EP2380592B1 (en) 2018-03-07
HUE036944T2 (hu) 2018-08-28
HUS1900035I1 (hu) 2019-07-29
BRPI0618705B8 (pt) 2021-05-25
US8007794B2 (en) 2011-08-30
US20090220489A1 (en) 2009-09-03
CA2626120A1 (en) 2007-05-18
US20170240623A1 (en) 2017-08-24
US9884908B2 (en) 2018-02-06
MY153249A (en) 2015-01-29
ES2433251T3 (es) 2013-12-10
US20160168244A1 (en) 2016-06-16
CN101309704B (zh) 2012-10-10
NO2019043I1 (no) 2019-12-09
PL2380592T3 (pl) 2018-07-31
US9890211B2 (en) 2018-02-13
US20180162931A1 (en) 2018-06-14
EP3069731A1 (en) 2016-09-21
US8734802B1 (en) 2014-05-27
DK3045182T3 (en) 2018-03-19
LUC00119I1 (es) 2019-05-15
PT3045182T (pt) 2018-06-05
EP1957106B2 (en) 2019-07-24
US20200247878A1 (en) 2020-08-06
ME00419B (me) 2011-10-10
JP5123197B2 (ja) 2013-01-16
SI1957106T1 (sl) 2014-02-28
ECSP088451A (es) 2008-07-30
EP1957106A2 (en) 2008-08-20
AU2006313434A1 (en) 2007-05-18
NL300997I1 (nl) 2019-07-03
CY2019019I1 (el) 2019-11-27
EP3045182B1 (en) 2018-03-07
ES2664854T3 (es) 2018-04-23
US9115194B2 (en) 2015-08-25
NO20190202A1 (no) 2008-05-19
SI2380592T1 (en) 2018-06-29
NO344605B1 (no) 2020-02-10
WO2007054809A2 (en) 2007-05-18
ZA200803484B (en) 2009-03-25
LTC2380592I2 (lt) 2020-05-11
SI3045182T1 (en) 2018-08-31
KR20110114705A (ko) 2011-10-19
DK1957106T3 (da) 2013-11-04
US8586045B2 (en) 2013-11-19
SV2008002905A (es) 2011-07-05
US20130216535A1 (en) 2013-08-22
US20220056114A1 (en) 2022-02-24
IL190876A (en) 2012-06-28
CY1120249T1 (el) 2019-07-10
BRPI0618705B1 (pt) 2018-02-06
CU20080088A7 (es) 2012-06-21
LUC00126I1 (es) 2019-07-09
AU2006313434B2 (en) 2011-10-27
IL190876A0 (en) 2008-11-03
ES2433251T5 (es) 2020-03-13
LUC00126I2 (es) 2019-12-27
CA2626120C (en) 2012-12-04
EP3178493A1 (en) 2017-06-14
LTPA2019015I1 (lt) 2019-08-26
US20240158481A1 (en) 2024-05-16
US20150291690A1 (en) 2015-10-15
DK2380592T3 (en) 2018-03-19
MA30136B1 (fr) 2009-01-02
EA015526B1 (ru) 2011-08-30
KR101250049B1 (ko) 2013-04-04
BRPI0618705A2 (pt) 2011-09-06
US9266951B2 (en) 2016-02-23
LUC00119I2 (es) 2020-07-10
CR9975A (es) 2008-06-02
US10329343B2 (en) 2019-06-25
US20120009192A1 (en) 2012-01-12
US20140147438A1 (en) 2014-05-29
JP2009515942A (ja) 2009-04-16
CY2019019I2 (el) 2019-11-27
PT2380592T (pt) 2018-06-06
RS20080200A (en) 2009-07-15
US20170240625A1 (en) 2017-08-24
SI1957106T2 (sl) 2019-09-30
LT2380592T (lt) 2018-05-10
PL1957106T3 (pl) 2014-03-31
UA94244C2 (ru) 2011-04-26
PT1957106E (pt) 2013-12-26
NL300997I2 (nl) 2019-11-28
WO2007054809A3 (en) 2007-08-09
PL3045182T3 (pl) 2018-07-31
HK1125837A1 (en) 2009-08-21
PL1957106T5 (pl) 2019-11-29
NO344099B1 (no) 2019-09-02
GEP20115333B (en) 2011-11-25
IL219503A0 (en) 2012-06-28
EP2380592A2 (en) 2011-10-26
RS57194B1 (sr) 2018-07-31
US20150361171A1 (en) 2015-12-17
US9365648B1 (en) 2016-06-14
US20170240624A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
CU23872B1 (es) Anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de calcitonina
FIC20230027I1 (fi) Tremelimumabi
FR2882056B1 (fr) Dipyrromethenes-bore borocarbones insatures
FI20065391A0 (fi) Anturointijärjestely
MA28857B1 (fr) Analogues de pipérazinyl-pyridine biaryliques substitués
DE502005004671D1 (de) Polyamid-EVA Mischungen
DE602006020042D1 (de) Zusammengesetzter sensor
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DE502005008436D1 (de) Gurtstraffer
DK1968623T3 (da) Bacteriocin-inducer-peptider
FI20060407A (fi) Syötin
DE502006004022D1 (de) Einspritzdüse
DE502005001932D1 (de) Radarsensor
DE602004008765D1 (de) Adaptiver Näherungssensor
FI20041538A0 (fi) Goniometri
DK2081952T3 (da) Peptider
FR2882055B1 (fr) Dibenzopyrromethenes-bore borocarbones insatures
DE202005000833U1 (de) Sitzmöbel
FIU20050091U0 (fi) Hieromalaite
SE0400111L (sv) Sensorarrangemang
ITMI20050395A1 (it) Cabina multifunzione
FR2883126B1 (fr) Binette multifonction
ES1059550Y (es) Cohete pirotecnico mejorado
DE202005000038U1 (de) Sitzmöbel
FI6843U1 (fi) Liitäntäkaivo

Legal Events

Date Code Title Description
FG Grant of patent